News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Sterling fell after reports Andy Burnham may run for Makerfield, and Deutsche Bank warned EUR/GBP risk premia have widened and could move further.
  • Rising U.S. Treasury yields and oil above $100 heighten inflation and geopolitical risks that could pressure richly valued U.S. equities.
  • Israeli airstrikes killed at least four in Gaza as indirect Israel-Hamas talks remain deadlocked, raising regional conflict risks.
  • Israel's economy contracted 3.3% annualized in Q1, with consumer spending down 4.7%, forcing growth forecasts lower amid the Iran conflict.
  • Investors are pivoting from geopolitics to U.S. Fed and fiscal risks, favoring long-duration bonds while watching energy-linked equities.
  • A White House-backed 'Rededicate 250' event drew conservative Christian leaders and criticism for privileging certain faiths and blurring church-state lines.

Latest Articles

Needham Lifts TransMedics Price Target to $174 After Strong Q4 Beat

Needham Lifts TransMedics Price Target to $174 After Strong Q4 Beat

Needham has increased its price target on TransMedics Group (TMDX) to $174 from $166 and kept a Buy rating after the company reported fourth-quarter 2025 results that outperformed consensus. Revenue and adjusted EPS exceeded estimates, management issued 2026 revenue guidance above expectations, and operational metrics including case volumes and mar…

Needham Lowers CoStar Group Target as Valuation Resets; Buys Remain Intact

Needham Lowers CoStar Group Target as Valuation Resets; Buys Remain Intact

Needham cut its price target on CoStar Group to $60 from $80 while keeping a Buy rating, citing a valuation reset despite solid quarterly performance and improving margins. CoStar beat top- and bottom-line expectations in the fourth quarter and posted sizable bookings growth, but its guidance for the coming periods came in below Street estimates an…

Brazil's BRB Restricted from Using Federal Loan Guarantees, Treasury Says

Brazil's BRB Restricted from Using Federal Loan Guarantees, Treasury Says

The Treasury Secretary announced that BRB is barred from contracting credit operations backed by federal guarantees amid fiscal concerns at its controlling shareholder, the Federal District government. Caixa Economica Federal is not pursuing acquisition or portfolio deals for BRB, and the bank may face more than 5 billion reais in provisioning afte…

Joby, Uber Begin Dubai Air Taxi Bookings as Joby Shares Gain

Joby, Uber Begin Dubai Air Taxi Bookings as Joby Shares Gain

Joby Aviation and Uber launched an integrated air taxi booking option in Dubai called Uber Air powered by Joby. The service enables riders to request Joby’s all-electric vertical takeoff and landing aircraft through the Uber app, with Joby anticipating its first passengers in Dubai later this year. The announcement coincided with a 7.5% rise in Job…

U.S. Trade Representative Says Current China Tariff Levels Will Hold

U.S. Trade Representative Says Current China Tariff Levels Will Hold

U.S. Trade Representative Jamieson Greer told a television audience that the administration does not plan to widen its tariff program on China and expects the present tariff regime to remain. He confirmed talks with China have touched on excess capacity and said certain duties will be set at 15%, with the possibility that some could exceed that rat…

AMN Healthcare: Contrarian Buy — Margin Recovery and Deep Value Ahead

AMN Healthcare: Contrarian Buy — Margin Recovery and Deep Value Ahead

AMN Healthcare is trading below $21 with an enterprise value around $1.52B, P/S 0.29 and free cash flow of $233.8M. Operational leverage from Nurse & Allied and the rollout of WorkWise create a plausible path to margin recovery. Combine that with a depressed valuation and active short interest, and the stock is a contrarian setup for a mid-term reb…

Morgan Stanley Highlights European Ad Agencies With AI Strengths

Morgan Stanley Highlights European Ad Agencies With AI Strengths

Morgan Stanley says select European advertising groups are holding up well despite worries about AI-driven disruption, keeping a preferred stance on several stocks. The broker singles out Publicis Groupe as its leading overweight pick for its integrated model and data assets, while assigning equal-weight ratings to WPP, Havas and S4 Capital amid va…

Needham nudges Cytokinetics target to $85 as trial readout looms

Needham nudges Cytokinetics target to $85 as trial readout looms

Needham increased its price objective on Cytokinetics (CYTK) to $85 from $84 and kept a Buy rating, citing limited launch information for Myqorzo and focus on a second-quarter 2026 ACACIA-HCM trial readout in non-obstructive hypertrophic cardiomyopathy as the next major catalyst. The stock is trading near its 52-week high after a recent rally, whil…

Rosenblatt Cuts Workday Price Target to $150 After Disappointing Guidance

Rosenblatt Cuts Workday Price Target to $150 After Disappointing Guidance

Rosenblatt reduced its price target on Workday to $150 while preserving a Buy rating following the company’s fourth-quarter results and fiscal-year guidance. Workday reported quarter results that met consensus but flagged weakened bookings and issued revenue and profit guidance below expectations. Shares are trading near 52-week lows as multiple an…

Cantor Fitzgerald Keeps Overweight on Supernus, Flags ONAPGO Supply Gains

Cantor Fitzgerald Keeps Overweight on Supernus, Flags ONAPGO Supply Gains

Cantor Fitzgerald reiterated an Overweight rating and a $63.00 price target on Supernus Pharmaceuticals after the company reported stronger-than-expected fiscal 2025 results and provided an update on supply for ONAPGO. Revenue beat, high gross margins and guidance for ONAPGO underpinned the call; Stifel adjusted its target to $55 while keeping a Ho…